The HemOnc Pulse
Blood Cancers Today brings you The HemOnc Pulse, a podcast covering all topics in the world of hematologic oncology.
CLL treatments are advancing—hear Dr. Wierda discuss resistance, remission, and future therapies on the HemOnc Pulse.
Dr. Hira Mian reviews selinexor, talquetamab, and emerging trispecifics shaping the future of multiple myeloma care.
In a podcast, experts explore chemo-free ALL therapies, CAR T breakthroughs, and the future of T-cell–targeted treatments.
Exploring treatment sequencing, prior therapy impact, and targeted approaches in lower-risk myelodysplastic syndromes.
A group of experts led by Naval Daver, MD discuss mutation loss, MRD dynamics, and transplant timing in evolving AML care.
Experts spotlight promising new CAR T-cell and bispecific therapies shaping the future of myeloma treatment.
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Updates From Other BCT Partners
Dr. Rakesh Popat joins the hosts of “Blood Cancer Talks” to highlight myeloma research presented at ASH 2024.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
The group discussed four abstracts on belantamab mafodotin in MM presented at EHA 2024 and ASCO 2024.
Andrew Evens, DO, MSc, FACP, discusses tailoring management by patient fitness in this setting plus recent clinical trials.
On this episode, Andrew Wei, MBBS, PhD, goes especially in depth regarding venetoclax plus azacitidine combination.
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.